Loading...
•
Jun 30, 2020
Annexon Q2 2020 Earnings Report
Announced second quarter 2020 financial results and recent highlights.
Key Takeaways
Annexon reported second quarter results, highlighting the completion of a $263M IPO in July and plans to initiate four new clinical trials by year-end. Cash and cash equivalents were $124.8 million as of June 30, 2020. Net loss attributable to common stockholders was $12.5 million or $28.87 per share for the quarter ended June 30, 2020.
Completed $263M IPO in July, and private financing in late June
Planning to initiate four new clinical trials by year-end, including in three expanded indications for ANX005 and first-in-human trial of ANX009
Phase 2 trials of ANX005 in GBS and ANX007 in GA remain on track for 2021
Michael Overdorf was appointed chief business officer to oversee corporate development and commercial strategy efforts
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...